OXALIPLATIN KABI 5mg / ml perfusive solution concentrate medication leaflet

L01XA03 oxaliplatin • Antineoplastic and immunomodulating agents | Other antineoplastic agents | Platinum compounds

Oxaliplatin is a chemotherapy agent used in the treatment of advanced or metastatic colorectal cancer. It works by binding to the DNA of tumor cells, inhibiting their replication and causing cell death.

The medication is administered intravenously, as directed by a doctor, usually in combination with other chemotherapy drugs. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as peripheral neuropathy, nausea, or diarrhea. It is important to inform the doctor of any unusual symptoms.

Common side effects include peripheral neuropathy, nausea, and diarrhea. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about OXALIPLATIN KABI 5mg / ml

Substance: oxaliplatin

Date of last drug list: 01-06-2025

Commercial code: W65013002

Concentration: 5mg / ml

Pharmaceutical form: perfusive solution concentrate

Quantity: 1

Product type: generic

Price: 111.10 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: FRESENIUS KABI ONCOLOGY PLC. - MAREA BRITANIE

Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA

Number: 10109/2017/02

Shelf life: 2 years after packing for marketing; dupa diluare 24 h la 2-8°C and 6 h la 15-25°C

Other substances similar to oxaliplatin

Compensation lists for OXALIPLATIN KABI 5mg / ml FRESENIUS

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

111.10 RON

111.10 RON

0.00 RON